Beta Blockers Global Market Report 2024

The beta blockers market has grown strongly in recent years. It will grow from $9.16 billion in 2023 to $9.78 billion in 2024 at a compound annual growth rate (CAGR) of 6.8%. During the historical period, the expansion primarily stemmed from advancements in managing hypertension, treating cardiovascular ailments, post-myocardial infarction care, prophylactic measures for migraines, and the effective management of anxiety and tremors.

The beta blockers market is expected to see strong growth in the next few years. It will grow to $12.28 billion in 2028 at a compound annual growth rate (CAGR) of 5.9%. The projected growth in the upcoming period is linked to the increased prevalence of cardiovascular diseases, wider utilization in heart failure treatments, the emergence of combination therapies, a concentrated emphasis on hypertension guidelines, and the exploration of new potential applications. Key trends anticipated in this period encompass the utilization of these medications in anxiety and performance-related scenarios, the potential neuroprotective effects they offer, the adoption of individualized treatment approaches, the influence of generic versions entering the market, and their integration with digital health platforms.

The escalation in cardiovascular disease incidents is anticipated to propel the beta blockers market's expansion. Cardiovascular diseases (CVDs) encompass various disorders affecting the heart and blood vessels. This surge primarily results from unhealthy diets, sedentary lifestyles, insufficient exercise, tobacco consumption, and obesity. Beta blockers offer substantial aid in reducing cardiovascular cases by exerting beneficial effects on the heart and blood vessels. Consequently, the rising prevalence of cardiovascular diseases significantly contributes to the growth of the beta blockers market. For instance, as per the Australian Bureau of Statistics' National Health Survey 2020-21, an estimated 571,000 Australians aged 18 and above (constituting 2.9% of the adult population) were living with coronary heart disease (CHD) in 2020-21.

The mounting prevalence of glaucoma is poised to drive the beta blockers market's expansion. Glaucoma comprises a group of eye conditions leading to vision impairment and potential blindness by harming the optic nerve responsible for transmitting visual information to the brain. Beta blockers play a pivotal role in managing glaucoma by reducing intraocular pressure (IOP). Their mechanism involves diminishing the production of aqueous humor, the eye's internal fluid, thereby alleviating the pressure within the eye. For instance, as reported by the BrightFocus Foundation in October 2022, over three million Americans are affected by glaucoma, with 2.7 million individuals aged 40 and older experiencing its most prevalent form, open-angle glaucoma. Globally, 80 million people are afflicted by glaucoma, a figure anticipated to surpass 111 million by 2040.

Product innovation emerges as a prominent trend gaining traction within the beta blockers market. Key market players are directing efforts toward creating innovative products to fortify their market positioning. Notably, in January 2021, Merck obtained U.S. Food and Drug Administration (FDA) approval for VERQUVO (vericiguat), a medication designed to treat heart failure with reduced ejection fraction (HFrEF) in adults. This drug facilitates blood vessel relaxation, reduces cardiac strain, and enhances cardiac function, signifying a notable innovation within the market.

Leading companies in the beta blockers sector are prioritizing the introduction of advanced beta blocking agents for severe hypertension management and blood pressure reduction, aiming to gain a competitive advantage. Beta blockers play a crucial role in addressing severe hypertension and lowering blood pressure by blocking peripheral arteriolar alpha-adrenoceptors, thus reducing peripheral resistance and safeguarding the heart from reflex sympathetic drive. For instance, in March 2023, Hikma Pharmaceuticals PLC launched Labetalol Hydrochloride (Labetalol HCl) Injection, USP, in prefilled syringe (PFS) form in the US for treating severe hypertension and reducing blood pressure. Labetalol combines selective alpha1-adrenergic blocking and nonselective beta-adrenergic blocking activities in a single substance, functioning primarily by blocking peripheral arteriolar alpha-adrenoceptors to decrease resistance and lower blood pressure.

In November 2021, Merck, a German pharmaceutical company, completed the acquisition of Acceleron Pharma Inc. The undisclosed transaction provided Merck access to a comprehensive range of potential therapies targeting multiple disease sectors, particularly cardiovascular diseases and hypertension. Acceleron Pharma Inc., a US-based biopharmaceutical firm, specializes in harnessing the capabilities of the transforming growth factor (TGF)-beta protein superfamily to innovate treatments for cardiovascular and various other diseases.

Major companies operating in the beta blockers market report are Pfizer Inc., Novartis AG, Merck & Co. Inc., AstraZeneca plc, Johnson and Johnson, Eli Lilly and Company, Sanofi SA, Bristol-Myers Squibb Company, Bayer AG, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Amneal Pharmaceuticals LLC, Abbott Laboratories, Eagle Pharmaceuticals Inc., Neon Healthcare Ltd., Midas Pharma GmbH, Global Calcium PVT. LTD., AbbVie Inc., Mylan N.V., Boehringer Ingelheim International GmbH, Aspen Pharmacare Holdings Limited, Lupin Limited, Torrent Pharmaceuticals Ltd., Dr. Reddy's Laboratories Ltd., Cipla Ltd., Sandoz International GmbH, Wockhardt Ltd., Endo Pharmaceuticals Inc., Apotex Inc.

North America was the largest region in the beta blockers market in 2023. Asia-Pacific is expected to be the fastest-growing region in the global beta-blockers market report during the forecast period. The regions covered in the beta blockers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the beta blockers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Within the beta blockers spectrum, two primary types include non-selective agents and selective agents. Non-selective agents within the beta-blockers market encompass medications that impede or obstruct beta-adrenergic receptors' effects without a specific affinity toward any particular subtype. These agents serve to regulate various physiological functions encompassing heart rate, blood pressure, bronchial smooth muscle tone, and peripheral vascular resistance. Their use spans across conditions such as angina pectoris, heart failure, high blood pressure, and other ailments, often managed through medications such as betaxolol, acebutolol, esmolol, among others. These drugs are available through hospital pharmacies, retail outlets, and online platforms, catering to the treatment of cardiac diseases, hypertension, glaucoma, and related conditions.

The beta blockers market research report provides beta blockers market statistics, including beta blockers industry global market size, regional shares, competitors with a beta blockers market share, detailed beta blockers market segments, market trends, and opportunities, and any further data you may need to thrive in the beta blockers industry. This beta blockers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The beta blockers market consists of sales of sales of metoprolol, nebivolol, timolol, and labetalol. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.